Glioblastoma

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Financial management, FDA, University, Cancer, FOLFIRINOX, Temozolomide, CendR, Safety, Pancreatic cancer, Conference call, Research, RNA, Osteosarcoma, GBM, National Health, Tumor microenvironment, PDAC, Therapy, Patient, SOC, Neoplasm, Data analysis, Glioblastoma, Projection, Pharmaceutical industry

BASKING RIDGE, N. J., May 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the three months ended March 31, 2024.

Key Points: 
  • “2024, a pivotal year for Lisata, is off to a very strong start,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata.
  • The trial is actively enrolling with enrollment completion expected by the end of the third quarter of 2024.
  • As of March 31, 2024, Lisata had cash, cash equivalents, and marketable securities of approximately $43.3 million.
  • Lisata will hold a live conference call today, May 9, 2024, at 4:30 p.m. Eastern Time to discuss financial results, provide a business update and answer questions.

Brain Cancer Canada awards The Dwayne Andrews Glioblastoma Grant for Research to a study on the impact of anesthetics on brain cancer proliferation

Retrieved on: 
Mittwoch, Mai 8, 2024
Family, Research, SAC, Glioblastoma, Patient safety, Brain, Patient, Metastasis, Anesthetic, LHSC, Lawson Health Research Institute, London Health Sciences Centre, Neuro, Medical imaging

The grant will fund a study at London Health Sciences Centre (LHSC) titled “Comparison of intravenous and inhaled anesthetics on brain tumour proliferation: an in-vitro study”.

Key Points: 
  • The grant will fund a study at London Health Sciences Centre (LHSC) titled “Comparison of intravenous and inhaled anesthetics on brain tumour proliferation: an in-vitro study”.
  • The work aims to assess whether anesthetics used during glioblastoma brain tumour surgery can impact tumour growth, invasion, and metastasis.
  • This grant reflects our commitment to supporting innovative research that can lead to better outcomes for brain cancer patients," she said.
  • Our team thanks Brain Cancer Canada, the Andrews Family and Auto|One Group for helping us kickstart our work through the Dwayne Andrews GBM Research Grant.”
    The grant is the first in a series of four to be issued by Brain Cancer Canada during May, Brain Cancer Awareness Month.

Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference

Retrieved on: 
Dienstag, Mai 7, 2024
Brain, Scientific method, Ionis Pharmaceuticals, Pancreatic cancer, Glioblastoma, Novo Nordisk, Viva Technology, Clinical trial, CNRS, Cancer, Biotechnology, Pharmaceutical industry

For this event, France’s National Center for Scientific Research (CNRS) has decided to highlight 10 start-ups developing disruptive technologies.

Key Points: 
  • For this event, France’s National Center for Scientific Research (CNRS) has decided to highlight 10 start-ups developing disruptive technologies.
  • In the field of Health, Vect-Horus has been selected to present its VECTrans® technology, unique in Europe, which represents a breakthrough innovation in drug targeting to the brain and other pathological tissues (e.g.
  • Vect-Horus Chief Scientific Officer Jean-Manuel Pean will take part in a roundtable, where he will present an overview of the Company and its pipeline.
  • More details on the definite roundtable program will be announced closer to the event.

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Retrieved on: 
Mittwoch, Mai 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, FXI, MTAP, Mutation, Safety, PARP, Pharmacokinetics, Carcinoma, Breast, STK11, BID, GBM, Glioblastoma, Culture, Journal, Novartis, Patient, Medicinal chemistry, Cancer, Collaboration, Clinical trial, Therapy, NSCLC, PRMT5, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2024, and provided business highlights.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2024, and provided business highlights.
  • Finally, we welcomed the newest member of our leadership team, Julie Carretero, as Chief Human Resources Officer.
  • Dose expansion is expected to initiate in the TNG462 phase 1/2 clinical trial in 2Q 2024.
  • General and administrative expenses were $10.7 million for the three months ended March 31, 2024, compared to $8.0 million for the same period in 2023.

BPGbio Brings Late Clinical Stage Rare Disease and Oncology Assets to US and EU Pharma Partnering Summits

Retrieved on: 
Dienstag, Mai 7, 2024
Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Neurology, FDA, Health, Breast cancer, Brain, Q10, HPC, Parkinson's disease, Carcinoma, Liver disease, Oak Ridge National Laboratory, State, Pancreatic cancer, Doctor of Philosophy, Tumor microenvironment, GBM, Epidermolysis bullosa, SCC, Therapy, Patient, Sarcopenia, Glioblastoma, Biomarker, Drug discovery, Orphan drug, EB, TME, Pharmaceutical industry

BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.

Key Points: 
  • BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.
  • BPM31510 acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
  • BPGbio is also exploring a late stage trial with BPM31510-IV/oral for primary coenzyme Q10 deficiency , an ultra-rare, potentially life threatening disease that affects the brain, muscles, and kidneys in afflicted patients.
  • This platform identifies targets, biomarkers, and drugs and assists the development team through both the development and clinical trial stages.

Strengthening CAR-T Therapy to Work Against Solid Tumors

Retrieved on: 
Mittwoch, Mai 8, 2024
Immunotherapy, Brain, University, Blood, Prostate, Protein, Mouse, Pancreas, Ovary, Safety, Public health, See, Cancer research, Glioblastoma, Genetic engineering, Invention, TMIGD2, Canadian Aviation Regulations, Urology, National Cancer Institute, Research, Leukemia, Chimera, Lymphoma, CD276, Liver, Microbiology, Medicine, Bone marrow, Neoplasm, Lung, Paper, Antigen, Zang, Immune system, Albert Einstein, Vaccine

"CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.

Key Points: 
  • "CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.
  • "We found that our changes to standard CAR-T cell therapy can significantly boost its effectiveness against solid tumors, including often-fatal pancreatic cancer and glioblastomas."
  • Dr. Zang and his colleagues created five CAR-T therapies that they tested on mice implanted with several types of solid human tumors.
  • He later realized that incorporating TMIGD2 into CAR-T cells might enable them to overcome the challenges posed by solid tumors.

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
Dienstag, April 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Retrieved on: 
Donnerstag, April 25, 2024
Glioma, Shanda, MET, WHO, Temozolomide, Safety, Risk, NMPA, National Medical Products Administration, Glioblastoma, Isocitrate dehydrogenase, Survival, New Drug Application, Cisplatin, Death, Central nervous system, Partnership, Trial of the century, Etoposide, OS, History, CNS, IDH, Patient, Neoplasm, Met, APLM, NSCLC, Lung cancer, Pharmaceutical industry

FOSTER CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that its partner in China, Avistone Biotechnology Co. Ltd. (Avistone), received approval from the National Medical Products Administration (NMPA) of China for vebreltinib (APL-101) for the treatment of adult patients with isocitrate dehydrogenase (IDH) mutant astrocytoma (WHO Grade 4) or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion (ZM fusion) gene and have failed previous treatments. This supplemental New Drug Application (sNDA) approval makes vebreltinib the world’s first c-Met inhibitor approved for treatment of Central Nervous System (CNS) tumor with c-Met alteration, and follows the NMPA’s November 2023 approval of vebreltinib for the treatment of patients with Met Exon 14 skipping non-small cell lung cancer (NSCLC).

Key Points: 
  • "The NMPA’s approval of vebreltinib in gliomas is an important, first-in-class approval as it demonstrates vebreltinib’s CNS penetration ability and c-Met inhibitory activity in the tumors there," said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics.
  • Surgery, radiation treatment, and chemotherapy are current standard treatment strategies for gliomas with poor prognoses.
  • These preliminary data support cross-region similarity of patient response to treatment with vebreltinib.
  • This collaboration enables both companies to leverage their strengths and maximize the benefit of vebreltinib worldwide.

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Mittwoch, April 24, 2024
Diamond, Patient, Cancer, Glioblastoma, GBM, Pharmaceutical industry

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO Annual Meeting, taking place May 31 – June 4 in Chicago, IL.

Key Points: 
  • CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO Annual Meeting, taking place May 31 – June 4 in Chicago, IL.
  • The two poster presentations describe data for BDTX-1535 in patients with recurrent glioblastoma (GBM) across two clinical trials: a Phase 1 dose escalation trial, for which topline data were released in December 2023 , and a Phase 0/1 “trigger” (“window of opportunity”) trial conducted as an Investigator Sponsored Trial at the Ivy Brain Tumor Center ( NCT06072586 ).
  • Presentation details are as follows:
    Title: Phase 1 Study of BDTX-1535, an Oral 4th Generation Covalent EGFR Inhibitor, in Patients with Recurrent Glioblastoma: Preliminary Dose Escalation Results
    Posters will become available on June 1, 2024 at 10:00 AM EDT on the Black Diamond Therapeutics website here .

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Retrieved on: 
Dienstag, April 23, 2024
PSMA, Brain, Cancer, Planet, Conference, Webcast, Glioblastoma, Prostate cancer, Indian stock exchange, Patient, Paris Las Vegas

The Company will also host in person one-on-one meetings with investors on Thursday, May 2, 2024.

Key Points: 
  • The Company will also host in person one-on-one meetings with investors on Thursday, May 2, 2024.
  • Conference Location: Paris Hotel & Casino in Las Vegas, NV
    Presentation Webcast: The webcasted presentation can be accessed at https://www.webcaster4.com/Webcast/Page/3026/50183 or on the Company's website at https://shuttlepharma.com/investor-relations/ .
  • 1x1 Meetings: Management will be participating in in-person one-on-one meetings at the event on Thursday, May 2, 2024.
  • To arrange a meeting with management, please contact your Planet MicroCap representative, or Lytham Partners at [email protected] .